2. Signaling Pathways
  3. GPCR/G Protein
  4. GnRH Receptor

GnRH Receptor

Gonadotropin releasing hormone receptor; GNRHR

GnRH Receptor

Related Products

PDF 0.35 MB

The GnRH receptor (Gonadotropin-releasing hormone receptor, GNRHR) is a member of the rhodopsin-like G protein-coupled receptor (GPCR) family and consists of seven transmembrane helical domains connected via extra- and intra-cellular segments. GnRH receptor is located on the plasma membrane of gonadotrophs, pituitary cells that synthesize the gonadotrophins LH and FSH.

Mammalian type I and II GnRH receptors show differential ligand preference for GnRH-I (also named as LHRHR) and GnRH-II, respectively. All GnRH receptors activate the Gq/11 family of G proteins, which activate phospholipase C-catalyzed production of second messengers that activate protein kinase C (PKC). GnRH receptor activated by GnRH analogues stimulates the synthesis and release of LH and FSH. GnRH receptors can be used for the research of breast and prostate cancer, regulation of fertility, endometriosis and a range of other medical and veterinary uses.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P4688
    (Ser(Ac)4,D-Ser(tBu)6,Azagly10)-LHRH
    (Ser(Ac)4,D-Ser(tBu)6,Azagly10)-LHRH is an important peptide hormone.
    (Ser(Ac)4,D-Ser(tBu)6,Azagly10)-LHRH
  • HY-P3583
    (Des-Gly10,D-Arg6,Pro-NHEt9)-LHRH II (chicken)
    Des-Gly10,D-Arg6,Pro-NHEt9)-LHRH II (chicken) is an active petide. (Des-Gly10,D-Arg6,Pro-NHEt9)-LHRH II (chicken) can be used for the research of various biochemical studies.
    (Des-Gly10,D-Arg6,Pro-NHEt9)-LHRH II (chicken)
  • HY-P3975
    Glp-His-Pro-Gly-NH2
    		Agonist
    Glp-His-Pro-Gly-NH2 (pGlu-His-Pro-Gly-NH2) is a peptide containing 4 amino acids. Glp-His-Pro-Gly-NH2 stimulates gonadotrophin, luteinizing hormone (LH) and follicle stimulating hormone (FSH) release.
    Glp-His-Pro-Gly-NH2
  • HY-P4739
    LHRH (1-5) (free acid)
    LHRH (1-5) (free acid) is a polypeptide generated by the cleavage of LHRH at the Tyr55-Gly66 site. LHRH (1-5) (free acid) is converted into LHRH (1-3) and LHRH (4-5) fragments under the catalysis of Angiotensin-converting enzyme (HY-P2983).
    LHRH (1-5) (free acid)
  • HY-P3084
    Human follicular gonadotropin releasing peptide
    Human follicular gonadotropin releasing peptide (hF-GRP) is a hormone peptide. Human follicular gonadotropin releasing peptide can stimulate pituitary luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion in vitro.
    Human follicular gonadotropin releasing peptide
  • HY-16532
    Zoptarelin doxorubicin
    Zoptarelin doxorubicin (AEZS-108; AN-152) is a hybrid anticancer agent, containing Zoptarelin and Doxorubicin. Zoptarelin doxorubicin has been used to research targeting tumors expressing LHRH receptors. Zoptarelin doxorubicin abolishes tumor progression and induces remarkable apoptosis in vitro.
    Zoptarelin doxorubicin
  • HY-P2446
    ORG 30276
    		Antagonist
    ORG 30276 (APTAA-LHRH) is a potent GnRH antagonist that effectively reduces serum LH and FSH levels in male rats. ORG 30276 significantly decreases unoccupied pituitary GnRH receptors, leading to suppressed gonadotropin secretion. ORG 30276 treatment results in a considerable reduction in mRNA levels of gonadotropin beta-subunits in the pituitary gland. ORG 30276's effects on gonadotropin dynamics can be selectively reversed by the replacement of specific sex steroids, with androgens being particularly effective for the FSH beta-subunit mRNA levels.
    ORG 30276
  • HY-14369S
    Elagolix-13C,d3 sodium
    		Antagonist
    Elagolix-13C,d3 (sodium) is the 13C- and deuterium labeled Elagolix sodium. Elagolix sodium is a human GnRH receptor (GnRHR) antagonist with an IC50 and Ki of 0.25 and 3.7 nM, respectively.
    Elagolix-<sup>13</sup>C,d<sub>3</sub> sodium
  • HY-P10378
    GPR10 agonist 1
    		Agonist
    GPR10 agonist 1 (compound 18-S4) is a potent GPR10 agonist with EC50 values of 80, 7.8 nM in the presence (10%) or absence (0%) of FBS, respectively. GPR10 agonist 1 has the potential for the research of chronic obesity.
    GPR10 agonist 1
  • HY-106279
    EA-230
    		Ligand 99.92%
    EA-230 is a synthetic oligopeptide originally derived from beta-human chorionic gonadotropin (beta-hCG) lysates. EA-230 has anti-inflammatory effects and can be used for the research of sepsis.
    EA-230
  • HY-P2419
    [Ala6]-LHRH
    		Agonist
    [Ala6]-LHRH is a synthetic luteinizing hormone-releasing hormone agonist, demonstrating effective stimulation of pituitary luteinizing hormone secretion. [Ala6]-LHRH enhances reproductive hormone regulation, contributing to fertility treatments. [Ala6]-LHRH plays a crucial role in managing conditions related to hormone imbalances.
    [Ala6]-LHRH
  • HY-16168AS
    Degarelix-d7
    		Antagonist
    Degarelix-d7 (FE 200486-d7 free base) is deuterium labeled Degarelix. Degarelix is a competitive and reversible gonadotropin-releasing hormone receptor (GnRHR) antagonist.
    Degarelix-d<sub>7</sub>
  • HY-P0056
    Histrelin
    		Agonist
    Histrelin, a GnRH analogue, is a GnRH Receptor agonist. Histrelin increases serum luteinising hormone (LH), follicle stimulating hormone (FSH) and testosterone levels. Histrelin can be used in the research of prostate cancer, endometriosis.
    Histrelin
  • HY-P3606
    GnRH Associated Peptide (1-24), human
    		Activator
    GnRH Associated Peptide (GAP) (1-24), human is the human gonadotropin-releasing hormone-associated peptide (GAP) 1-24 fragment (hGAP-1-24). GAP is joined to the luteinizing hormone-releasing hormone (LH-RH) sequence by a 3 amino acid processing site.
    GnRH Associated Peptide (1-24), human
  • HY-P4568
    (D-Ser4,D-Ser(tBu)6,Azagly10)-LHRH
    (D-Ser4,D-Ser(tBu)6,Azagly10)-LHRH is an analogue of luteinizing hormone-releasing hormone (LHRH). LHRH plays a central role in the control of reproduction by stimulating the release of pituitary luteinizing hormone (LH) and follicle-stimulating hormone (FSH).
    (D-Ser4,D-Ser(tBu)6,Azagly10)-LHRH
  • HY-P3675
    LH-RH (4-10)
    		Activator
    LH-RH (4-10) is a heptapeptide, one of major degradation products of luteinising-hormone releasing hormone (LHRH) via pituitary and hypothalamus. LH-RH (4-10) produced in macrophages and type II pneumocytes.
    LH-RH (4-10)
  • HY-P3671
    [D-Glp1,D-Phe2,D-Trp3,6]-LH-RH
    		Antagonist
    [D-Glp1,D-Phe2,D-Trp3,6]-LH-RH is a Luteinizing-hormone-releasing hormone (LHRH) analogue. [D-Glp1,D-Phe2,D-Trp3,6]-LH-RH acts as a GnRH receptor antagonist.
    [D-Glp1,D-Phe2,D-Trp3,6]-LH-RH
  • HY-P4693
    (Ser(tBu)6,Azagly10)-LHRH
    (Ser(tBu)6,Azagly10)-LHRH is a potent aza-GLY analog.
    (Ser(tBu)6,Azagly10)-LHRH
  • HY-P3666
    [D-Phe2,6, Pro3]-LH-RH
    [D-Phe2,6, Pro3]-LH-RH is a potent luteinizing hormone releasing hormone (LHRH) antagonist.
    [D-Phe2,6, Pro3]-LH-RH
  • HY-P4144
    Onvitrelin ucalontide
    Onvitrelin ucalontide ([Phor18-LHRH (338613)]) is an analogue of luteinizing hormone releasing hormone (LHRH) with antineoplastic activity. Onvitrelin ucalontide is a peptide with sequences of KFAKFAKKFAKFAKKFAKQHWSYGLRPG. Onvitrelin ucalontide effectively inhibits breast cancer, ovarian cancer and prostate cancer xenografts in mouse model.
    Onvitrelin ucalontide
Cat. No. Product Name / Synonyms Application Reactivity